Methods useful in the treatment of bone resorption diseases
View Patent ↗The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
1. A method for the treatment of osteoporosis in humans comprising:
administering to said human an effective amount of parathyroid hormone during a period of approximately 6 to 24 months; and
after the administration of said parathyroid hormone has been terminated, optionally administering a bone resorption inhibitor during a period of approximately 6 to 36 months.
2. A method according to claim 1 , wherein the parathyroid hormone is selected from (a) full-length parathyroid hormone; (b) biologically active variants of full-length parathyroid hormone; (c) biologically active parathyroid hormone fragments; and (d) biologically active variants of parathyroid hormone fragments.
3. A method according to claim 1 , wherein administering to said human an effective amount of parathyroid hormone, consists of administering a human PTH (1-84) during a period of approximately 6 to 24 months.
4. A method according to claim 1 , wherein administering to said human an effective amount of parathyroid hormone, consists of administering once daily a human PTH (1-84) dose of 50 μg to 100 μg during a period of approximately 6 to 24 months.
5. A method according to claim 1 , wherein the optionally administering a bone resorption inhibitor comprises administering a bone resorption inhibitor selected from the group consisting of bisphosphonate, a selective estrogen receptor modulator, calcitonin, a vitamin D analog, and a calcium salt.
6. A method according to claim 1 , wherein the said human is a post-menopausal female.
7. A method for the enhancement of bone mineral density in a human needing enhancement of bone density, the method comprising:
optionally administering, to a human who has already been subject to treatment with parathyroid hormone during a period of approximately 6 to 24 months, after the administration of parathyroid hormone has been terminated, an effective amount of a bone resorption inhibitor during a period of approximately 6 to 36 months.
8. A method according to claim 7 , wherein the optionally administering a bone resorption inhibitor comprises administering a bone resorption inhibitor selected from the group consisting of bisphosphonate, a selective estrogen receptor modulator, calcitonin, a vitamin D analog, and a calcium salt.
9. A method according to claim 7 , wherein the said human is a post-menopausal female.